Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer - Matthew Roe
UroToday is excited to host a lecture from a leading cardiologist’s perspective, Dr. Matthew Roe from Duke Clinical Research Institute. Dr. Roe’s discussion features the topics: atherosclerotic plaque formation and plaque instability and incidences of prostate cancer and cardiovascular events. In addition, cardiovascular risks with androgen deprivation therapy, GNRH antagonists and GnRH agonists.
Matthew T. Roe, MD, MHS
Faculty Director, Global Outcomes Commercial Megatrials
DCRI Fellowship Program Director
Associate Professor of Medicine
Duke Clinical Research Institute